Back to today’s briefing

Story perspectives

Biotech Boom: $1.3B Deals and Promising Treatments Unveiled

1/15/2025

38 6

Summary

Story summary

The J.P. Morgan Healthcare Conference in San Francisco is buzzing with groundbreaking biotech collaborations, highlighted by a staggering $1.3 billion partnership between Lonza and Boehringer. Denali Therapeutics is gearing up to seek regulatory approval for its promising Hunter syndrome treatment. Meanwhile, Roche perseveres in its Parkinson's research, and AbbVie teams up with Simcere for a potential $1.05 billion trispecific antibody.

1 of 1

Story summary

The J.P. Morgan Healthcare Conference in San Francisco is buzzing with groundbreaking biotech collaborations, highlighted by a staggering $1.3 billion partnership between Lonza and Boehringer. Denali Therapeutics is gearing up to seek regulatory approval for its promising Hunter syndrome treatment. Meanwhile, Roche perseveres in its Parkinson's research, and AbbVie teams up with Simcere for a potential $1.05 billion trispecific antibody.